Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 16

2347P - Correlation between second primary cancers and first primary cancers: A systematic review and meta-analysis of 9 million cancer patients

Date

21 Oct 2023

Session

Poster session 16

Topics

Pathology/Molecular Biology;  Cancer Epidemiology

Tumour Site

Presenters

Xinyu Wang

Citation

Annals of Oncology (2023) 34 (suppl_2): S1190-S1201. 10.1016/S0923-7534(23)01928-2

Authors

X. Wang1, M. Zeng1, A. Lin2, C. Zhou2, J. Zhang2, P. Luo2

Author affiliations

  • 1 Department Of Oncology, Zhujiang Hospital of Southern Medical University, 510282 - Guangzhou/CN
  • 2 Department Of Oncology, Zhujiang Hospital of Southern Medical University, 501280 - Guangzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2347P

Background

Many survivors of first primary cancers (FPCs) are at risk of developing a second primary cancer (SPC), the development of which usually leads to a worse prognosis. The development of SPCs may be closely related to the FPC. Different primary cancers have differentially high frequencies of specific SPC development. Our aim was to explore the possible correlation between the SPCs and FPCs.

Methods

We retrospectively searched and screened relevant literature on SPCs from four databases, namely, PubMed, EMBASE, Web of Science, and PMC. We also collected data on 28 different organ sites and the number of patients with SPC from The Surveillance, Epidemiology, and End Results (SEER) 8 Registry Database and NHANES database.

Results

A total of 9,617,643 patients with a FPC and 677,430 patients with a SPC were included in this meta-analysis. Patients with first primary gynaecological cancer and thyroid cancer developed second primary breast cancer and colorectal cancer more frequently. Patients with first primary head and neck cancer, anal cancer and esophageal cancer developed second primary lung cancer more frequently. Patients with first primary bladder cancer and penile cancer developed second primary lung cancer and prostate cancer more frequently. Patients with second primary bladder cancer accounted for 56% of first primary ureteral cancer patients with SPCs.

Conclusions

We recommend close clinical follow-up, monitoring and appropriate interventions in patients with relevant FPCs for better screening and early diagnosis of SPCs to prolong patient survival.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Peng Luo.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.